BiotechTube

Omalizumab + Omalizumab + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Symptomatic Dermographism

Conditions

Symptomatic Dermographism

Trial Timeline

Dec 1, 2012 → Dec 1, 2014

NCT ID
NCT02169115

About Omalizumab + Omalizumab + Placebo

Omalizumab + Omalizumab + Placebo is a phase 2 stage product being developed by Novartis for Symptomatic Dermographism. The current trial status is completed. This product is registered under clinical trial identifier NCT02169115. Target conditions include Symptomatic Dermographism.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02169115Phase 2Completed
NCT01580592Phase 2Completed

Competing Products

20 competing products in Symptomatic Dermographism

See all competitors
ProductCompanyStageHype Score
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
77
ISV-305Sun PharmaceuticalPhase 3
77
rabeprazole sodium + PlaceboEisaiPhase 3
77
Verinurad + Febuxostat + DapagliflozinAstraZenecaPhase 2
52
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
41
Esomeprazole + Matching placeboAstraZenecaPhase 3
77
DFV890 + PlaceboNovartisPhase 2
52
Pasireotide + OctreotideNovartisPhase 3
77
TegaserodNovartisPhase 2
52
valsartanNovartisApproved
85
Atorvastatin - Cholestyramine - SitosterolPfizerPre-clinical
22
Epoetin biosimilarPfizerPre-clinical
22
Apixaban + Standard of carePfizerPhase 3
76
Azithromycin plus chloroquinePfizerPhase 3
76
MavacamtenBristol Myers SquibbApproved
84
Aficamten + PlaceboSanofiPhase 3
76
Vandetanib 300 mgSanofiPre-clinical
22
REGN7508 + Acetylsalicylic Acid (ASA) + PlaceboRegeneron PharmaceuticalsPhase 3
76
Rivaroxaban + PlaceboBayerPhase 3
74
Droxidopa capsules + Placebo capsulesLundbeckApproved
82

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85